A randomized controlled trial of desvenlafaxine-induced structural brain changes in the treatment of persistent depressive disorder

Aizenstein, 2009, Altered functioning of the executive control circuit in late-life depression: episodic and persistent phenomena, Am. J. Geriatr. Psychiatry, 17, 30, 10.1097/JGP.0b013e31817b60af Alexopoulos, 2012, Functional connectivity in the cognitive control network and the default mode network in late-life depression, J. Affect. Disord., 139, 56, 10.1016/j.jad.2011.12.002 Andrade, 2009, Desvenlafaxine, Indian J. Psychiatry, 51, 320, 10.4103/0019-5545.58303 Arnone, 2013, State-dependent changes in hippocampal grey matter in depression, Mol. Psychiatry, 18, 1265, 10.1038/mp.2012.150 Bansal, 2018, Evidence for neuroplastic compensation in the cerebral cortex of persons with depressive illness, Mol. Psychiatry, 23, 375, 10.1038/mp.2017.34 Bartlett, 2018, Pretreatment and early-treatment cortical thickness is associated with SSRI treatment response in major depressive disorder, Neuropsychopharmacology, 43, 2221, 10.1038/s41386-018-0122-9 Blanco, 2010, The epidemiology of chronic major depressive disorder and dysthymic disorder: results from the National Epidemiologic Survey on Alcohol and Related Conditions, J. Clin. Psychiatry, 71, 1645, 10.4088/JCP.09m05663gry Bora, 2012, Gray matter abnormalities in Major Depressive Disorder: a meta-analysis of voxel based morphometry studies, J. Affect. Disord., 138, 9, 10.1016/j.jad.2011.03.049 Boyer, 2008, Efficacy, safety, and tolerability of fixed-dose desvenlafaxine 50 and 100 mg/day for major depressive disorder in a placebo-controlled trial, Int Clin Psychopharmacol, 23, 243, 10.1097/YIC.0b013e32830cebed Broyd, 2009, Default-mode brain dysfunction in mental disorders: a systematic review, Neurosci. Biobehav. Rev., 33, 279, 10.1016/j.neubiorev.2008.09.002 Chen, 2007, Brain imaging correlates of depressive symptom severity and predictors of symptom improvement after antidepressant treatment, Biol. Psychiatry, 62, 407, 10.1016/j.biopsych.2006.09.018 Chumbley, 2010, Topological FDR for neuroimaging, Neuroimage, 49, 3057, 10.1016/j.neuroimage.2009.10.090 Clasen, 2014, Cognitive control network connectivity in adolescent women with and without a parental history of depression, Dev. Cogn. Neurosci., 7, 13, 10.1016/j.dcn.2013.10.008 Clayton, 2015, Desvenlafaxine 50 and 100mg/d versus placebo for the treatment of major depressive disorder: a phase 4, randomized controlled trial, J. Clin. Psychiatry, 76, 562, 10.4088/JCP.13m08978 Cole, 2007, The cognitive control network: integrated cortical regions with dissociable functions, Neuroimage, 37, 343, 10.1016/j.neuroimage.2007.03.071 Coryell, 2005, Subgenual prefrontal cortex volumes in major depressive disorder and schizophrenia: diagnostic specificity and prognostic implications, Am. J. Psychiatry, 162, 1706, 10.1176/appi.ajp.162.9.1706 Costafreda, 2009, Prognostic and diagnostic potential of the structural neuroanatomy of depression, PLoS One, 4, 10.1371/journal.pone.0006353 Davis, 2020, Discovery and validation of biomarkers to aid the development of safe and effective pain therapeutics: challenges and opportunities, Nat. Rev. Neurol., 16, 381, 10.1038/s41582-020-0362-2 Deecher, 2006, Desvenlafaxine succinate: a new serotonin and norepinephrine reuptake inhibitor, J. Pharmacol. Exp. Ther., 318, 657, 10.1124/jpet.106.103382 Drevets, 2007, Orbitofrontal cortex function and structure in depression, Ann N Y Acad Sci, 1121, 499, 10.1196/annals.1401.029 Drevets, 2008, The subgenual anterior cingulate cortex in mood disorders, CNS Spectr., 13, 663, 10.1017/S1092852900013754 Dunner, 2001, Acute and maintenance treatment of chronic depression, J. Clin. Psychiatry, 62, 10 Feurer, 2021, Anterior cingulate cortex activation during attentional control as a transdiagnostic marker of psychotherapy response: a randomized clinical trial, Neuropsychopharmacology Fournier, 2010, Antidepressant drug effects and depression severity: a patient-level meta-analysis, JAMA, 303, 47, 10.1001/jama.2009.1943 Freidlin, 2014, Biomarker enrichment strategies: matching trial design to biomarker credentials, Nat. Rev. Clin. Oncol., 11, 81, 10.1038/nrclinonc.2013.218 Frodl, 2004, Hippocampal and amygdala changes in patients with major depressive disorder and healthy controls during a 1-year follow-up, J. Clin. Psychiatry, 65, 492, 10.4088/JCP.v65n0407 Frodl, 2008, Depression-related variation in brain morphology over 3 years: effects of stress?, Arch. Gen. Psychiatry, 65, 1156, 10.1001/archpsyc.65.10.1156 Fu, 2015, Multimodal functional and structural neuroimaging investigation of major depressive disorder following treatment with duloxetine, BMC Psychiatry, 15, 82, 10.1186/s12888-015-0457-2 Geddes, 2003, Relapse prevention with antidepressant drug treatment in depressive disorders: a systematic review, Lancet, 361, 653, 10.1016/S0140-6736(03)12599-8 Gerlach, 2022, MRI predictors of pharmacotherapy response in major depressive disorder, Neuroimage Clin, 36, 10.1016/j.nicl.2022.103157 Gusnard, 2001, Role of medial prefrontal cortex in a default mode of brain function, Neuroimage, 13, 10.1016/S1053-8119(01)91757-4 Gusnard, 2001, Medial prefrontal cortex and self-referential mental activity: relation to a default mode of brain function, Proc. Natl. Acad. Sci. U.S.A., 98, 4259, 10.1073/pnas.071043098 Gyurak, 2016, Frontoparietal Activation During Response Inhibition Predicts Remission to Antidepressants in Patients With Major Depression, Biol. Psychiatry, 79, 274, 10.1016/j.biopsych.2015.02.037 Hamilton, 1960, A rating scale for depression, J. Neurol. Neurosurg. Psychiatry, 23, 56, 10.1136/jnnp.23.1.56 Hastings, 2004, Volumetric analysis of the prefrontal cortex, amygdala, and hippocampus in major depression, Neuropsychopharmacology, 29, 952, 10.1038/sj.npp.1300371 Hellerstein, 2000, Double-blind comparison of sertraline, imipramine, and placebo in the treatment of dysthymia: effects on personality, Am. J. Psychiatry, 157, 1436, 10.1176/appi.ajp.157.9.1436 Hellerstein, 2019, Desvenlafaxine vs. placebo in the treatment of persistent depressive disorder, J. Affect. Disord., 245, 403, 10.1016/j.jad.2018.11.065 Hellerstein, 2012, A Randomized Controlled Trial of Duloxetine Versus Placebo in the Treatment of Nonmajor Chronic Depression, J. Clin. Psychiatry, 73, 984, 10.4088/JCP.11m07230 Hung, 2023, Differences in gray matter volumes of subcortical nuclei between major depressive disorder with and without persistent depressive disorder, J. Affect. Disorders, 321, 161, 10.1016/j.jad.2022.10.021 Jobst, 2016, European Psychiatric Association Guidance on psychotherapy in chronic depression across Europe, Eur. Psychiatry, 33, 18, 10.1016/j.eurpsy.2015.12.003 Kambe, 2018, Severity of Depressive Symptoms and Volume of Superior Temporal Gyrus in People Who Visit a Memory Clinic Unaccompanied, Dement Geriatr. Cogn. Dis. Extra, 8, 207, 10.1159/000489008 Keller, 2000, A comparison of nefazodone, the cognitive behavioral-analysis system of psychotherapy, and their combination for the treatment of chronic depression, N. Engl. J. Med., 342, 1462, 10.1056/NEJM200005183422001 Kirsch, 2008, Initial severity and antidepressant benefits: a meta-analysis of data submitted to the Food and Drug Administration, PLoS Med., 5, e45, 10.1371/journal.pmed.0050045 Kong, 2014, Frontal-subcortical volumetric deficits in single episode, medication-naive depressed patients and the effects of 8 weeks fluoxetine treatment: a VBM-DARTEL study, PLoS One, 9, e79055, 10.1371/journal.pone.0079055 Koolschijn, 2009, Brain volume abnormalities in major depressive disorder: a meta-analysis of magnetic resonance imaging studies, Hum. Brain Mapp., 30, 3719, 10.1002/hbm.20801 Li, 2022, Abnormal core functional connectivity on the pathology of MDD and antidepressant treatment: a systematic review, J. Affect. Disord., 296, 622, 10.1016/j.jad.2021.09.074 Liebowitz, 2008, Efficacy, safety, and tolerability of desvenlafaxine 50 mg/day and 100 mg/day in outpatients with major depressive disorder, Curr Med Res Opin, 24, 1877, 10.1185/03007990802161923 Liebowitz, 2010, Efficacy, safety, and tolerability of Desvenlafaxine 50mg/d for the treatment of major depressive disorder:a systematic review of clinical trials, Prim Care Companion J. Clin. Psychiatry, 12 Liu, 2017, From Serotonin to Neuroplasticity: evolvement of Theories for Major Depressive Disorder, Front. Cell Neurosci., 11, 10.3389/fncel.2017.00305 Liu, 2018, The abnormal functional connectivity between the hypothalamus and the temporal gyrus underlying depression in Alzheimer's disease patients, Front. Aging Neurosci., 10, 10.3389/fnagi.2018.00037 Lyoo, 2002, Decrease in genu of the corpus callosum in medication-naive, early-onset dysthymia and depressive personality disorder, Biol. Psychiatry, 52, 1134, 10.1016/S0006-3223(02)01436-1 MacQueen, 2008, Posterior hippocampal volumes are associated with remission rates in patients with major depressive disorder, Biol. Psychiatry, 64, 880, 10.1016/j.biopsych.2008.06.027 Martens, 2021, Resting state functional connectivity patterns as biomarkers of treatment response to escitalopram in patients with major depressive disorder, Psychopharmacology McCarthy, 2013, Attention network hypoconnectivity with default and affective network hyperconnectivity in adults diagnosed with attention-deficit/hyperactivity disorder in childhood, JAMA Psychiatry, 70, 1329, 10.1001/jamapsychiatry.2013.2174 Murphy, 2012, Prevalence and correlates of the proposed DSM-5 diagnosis of Chronic Depressive Disorder, J. Affect. Disord., 139, 172, 10.1016/j.jad.2012.01.033 Pampallona, 2004, Combined pharmacotherapy and psychological treatment for depression: a systematic review, Arch. Gen. Psychiatry, 61, 714, 10.1001/archpsyc.61.7.714 Peterson, 2009, Cortical thinning in persons at increased familial risk for major depression, Proc. Natl. Acad. Sci. U. S. A., 106, 6273, 10.1073/pnas.0805311106 Pillay, 1998, A quantitative magnetic resonance imaging study of caudate and lenticular nucleus gray matter volume in primary unipolar major depression: relationship to treatment response and clinical severity, Psychiatry Res., 84, 61, 10.1016/S0925-4927(98)00048-1 Posner, 2013, Antidepressants normalize the default mode network in patients with dysthymia, JAMA Psychiatry, 70, 373, 10.1001/jamapsychiatry.2013.455 Preuss, 2020, SSRI treatment response prediction in depression based on brain activation by emotional stimuli, Front. Psychiatry, 11, 10.3389/fpsyt.2020.538393 Qiu, 2020, Resting-state functional connectivity of the anterior cingulate cortex in young adults depressed patients with and without suicidal behavior, Behav. Brain Res., 384, 10.1016/j.bbr.2020.112544 Rabkin, 1992, General versus systematic inquiry about emergent clinical events with SAFTEE: implications for clinical research, J. Clin. Psychopharmacol., 12, 3, 10.1097/00004714-199202000-00002 Raichle, 2001, A default mode of brain function, Proc. Natl. Acad. Sci. U.S.A., 98, 676, 10.1073/pnas.98.2.676 Ramezani, 2014, Temporal-lobe morphology differs between healthy adolescents and those with early-onset of depression, Neuroimage-Clin., 6, 145, 10.1016/j.nicl.2014.08.007 Reed, 2021, Neuroplastic effects of a selective serotonin reuptake inhibitor in relearning and retrieval, Neuroimage, 236, 10.1016/j.neuroimage.2021.118039 Rolls, 2019, The orbitofrontal cortex and emotion in health and disease, including depression, Neuropsychologia, 128, 14, 10.1016/j.neuropsychologia.2017.09.021 Rolls, 2020, The orbitofrontal cortex: reward, emotion and depression, Brain Commun., 2, fcaa196, 10.1093/braincomms/fcaa196 Rolls, 2019, Functional connectivity of the anterior cingulate cortex in depression and in health, Cereb. Cortex, 29, 3617, 10.1093/cercor/bhy236 Rush, 1998, The treatment of chronic depression, part 1: study design and rationale for evaluating the comparative efficacy of sertraline and imipramine as acute, crossover, continuation, and maintenance phase therapies, J. Clin. Psychiatry, 59, 589, 10.4088/JCP.v59n1106 Saricicek Aydogan, 2019, Cortical thickening in remitters compared to non-remitters with major depressive disorder following 8-week antidepressant treatment, Acta Psychiatr. Scand., 140, 217, 10.1111/acps.13065 Satyanarayana, 2009, Prevalence and correlates of chronic depression in the Canadian community health survey: mental health and well-being, Can. J. Psychiatry, 54, 389, 10.1177/070674370905400606 Scheuerecker, 2010, Orbitofrontal volume reductions during emotion recognition in patients with major depression, J. Psychiatry Neurosci., 35, 311, 10.1503/jpn.090076 Shah, 1998, Cortical grey matter reductions associated with treatment-resistant chronic unipolar depression. Controlled magnetic resonance imaging study, Br. J. Psychiatry, 172, 527, 10.1192/bjp.172.6.527 Shattuck, 2002, BrainSuite: an automated cortical surface identification tool, Med. Image Anal., 8, 129, 10.1016/S1361-8415(02)00054-3 Sheline, 2012, Treatment course with antidepressant therapy in late-life depression, Am. J. Psychiatry, 169, 1185, 10.1176/appi.ajp.2012.12010122 Sheline, 2010, Resting-state functional MRI in depression unmasks increased connectivity between networks via the dorsal nexus, Proc. Natl. Acad. Sci. U.S.A., 107, 11020, 10.1073/pnas.1000446107 Sled, 1998, A nonparametric method for automatic correction of intensity nonuniformity in MRI data, IEEE Trans. Med. Imaging, 17, 87, 10.1109/42.668698 Snyder, 2013, Major depressive disorder is associated with broad impairments on neuropsychological measures of executive function: a meta-analysis and review, Psychol. Bull., 139, 81, 10.1037/a0028727 Spitzer, 1992, The Structured Clinical Interview for DSM-III-R (SCID). I: history, rationale, and description, Arch. Gen. Psychiatry, 49, 624, 10.1001/archpsyc.1992.01820080032005 Suh, 2019, Cerebral cortical thickness after treatment with desvenlafaxine succinate in major depressive disorder, Neuroreport, 30, 378, 10.1097/WNR.0000000000001211 Takahashi, 2010, An MRI study of the superior temporal subregions in patients with current and past major depression, Prog. Neuropsychopharmacol. Biol. Psychiatry, 34, 98, 10.1016/j.pnpbp.2009.10.005 Tebartz van Elst, 1999, Amygdala enlargement in dysthymia–a volumetric study of patients with temporal lobe epilepsy, Biol. Psychiatry, 46, 1614, 10.1016/S0006-3223(99)00212-7 Tourian, 2009, Desvenlafaxine 50 and 100mg/d in the treatment of major depressive disorder: an 8-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group trial and a post hoc pooled analysis of three studies, Clin. Ther., 31, 1405, 10.1016/j.clinthera.2009.07.006 Vakili, 2000, Hippocampal volume in primary unipolar major depression: a magnetic resonance imaging study, Biol. Psychiatry, 47, 1087, 10.1016/S0006-3223(99)00296-6 van Tol, 2010, Regional brain volume in depression and anxiety disorders, Arch. Gen. Psychiatry, 67, 1002, 10.1001/archgenpsychiatry.2010.121 Viola, 1995, Alignment by Maximization of Mutual Information, 16 Wang, 2018, On enrichment strategies for biomarker stratified clinical trials, J. Biopharm. Stat., 28, 292, 10.1080/10543406.2017.1379532 Wason, 2014, Adaptive designs for clinical trials assessing biomarker-guided treatment strategies, Br. J. Cancer, 110, 1950, 10.1038/bjc.2014.156 Weissman, 1988, The epidemiology of dysthymia in five communities: rates, risks, comorbidity, and treatment, Am. J. Psychiatry, 145, 815, 10.1176/ajp.145.7.815 Yang, 2022, Serotonin-norepinephrine reuptake inhibitor antidepressant effects on regional connectivity of the thalamus in persistent depressive disorder: evidence from two randomized, double-blind, placebo-controlled clinical trials, Brain Commun., 4, fcac100, 10.1093/braincomms/fcac100